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A conservative position would be the following: 
God Technique Laboratory LNcl Efficiency 
Early detection DNA, RNA Not esubhshed Quertiomble 
amplificaaon 
Sequencing 
Speder idcntification Accuprobe. PCR-RFLF’, RL Yes 
Raiunce tesring Genotype testmg RL in areas YCS 
with MDR-TB 
Epldcmiology a d  
quality control W L P  RL YCS 
RL: Reference Laboratory 
At today‘s costs and lutllted automation, the conditions for an 
effective implementation of these techniques are generally only ful- 
filled by reference laboratories. 
Towards consensus in sensitivity testing 
ESCMID Working Party on Antibiotic 
Breakpoints, Interactive Session 
1 s1201 Problems in susceptibility testing: looking for a 
consensus 
F. Goldstein ’, F. Baquero ’, R. A~ckenthaler~. ’HGpital St.-joseph, 
Paris, France, ‘Hospital Ramon y Cajal, Madrid, Spain, ’HGpital 
Cantonal, Genbe, Switzerland 
Antibiotic susceptibility testmg varies &om country to counby ac- 
cordmg to the recommendations of national antimicrobial suscepti- 
bility testing committees. 
Objectives: To obtain the reactions fium the participating audi- 
ence in order to achieve a consensus for future susceptibility testing. 
Methods: This session will use an interactive audience response 
system to create a dynamic exchange between the audiences and 
the speakers. Following subjects will be covered minimal panels for 
susceptibility testing for clinical use and for the surveillance of resis- 
tance mechanisms, interpretive standards for streptococci including 
crossresistance for betalactam antibiotics or macrolides in S. pneumo- 
n ia ,  detection of the various resistance mechanisms of enterococci, 
definition of breakpoints for perod or parented cephalosporines, 
fixed or proportional ratio of betalactamase inhibitors, reporting of 
inducible cephalosporinase, methods to detect extended spectrum 
betalactamase producing enterobacteriaceae and methods to detect 
resistance mechanisms to fluoroquinolones. The problem of report- 
ing susceptible organisms according to breakpoint but with a de- 
tectable resistance mechanism will be discussed. The question of 
optimal quality control of susceptibility testing by creating a battery 
of reference strains with defined resistance mechanisms covering a 
broader range of MIC’S will be suggested. 
1 s121 I Development of NCCLS Antimicrobial 
Susceptibility Testing guidelines in the global 
environment 
M.J. Ferraro. Mass General Hospital, Harvard Medical School, Boston, 
MA, USA 
NCCLS is a global association ofmore than 2100 organizations and 
institutions in 46 different countries. NCCLS standards, guidelines, 
products, and services promote the delivery of quality patient test- 
ing and healthcare. The NCCLS Subcommittee on Antimicrobial 
Susceptibility Testing is composed of representatives &om microbi- 
ology laboratories, government, health care providers and educators, 
and pharmaceutical and diagnostic microbiology industries. Using 
the NCCLS consensus process, the subcommittee develops stan- 
dards that promote accurate antimicrobial susceptibility testing and 
appropriate reporting. The Subcommittee’s goals are to: 1. develop 
standard reference methods; 2. provide quality control parameters; 3. 
estabhh interpretive criteria; 4. provide suggestions regardug groups 
of antimicrobial agents for testing that encourage clinidy relevant 
and cost-effective laboratory testing; 5. continually refine standards 
and optimize detection of emerging resistance mechanism through 
the development of new or revised methods, interpretive criteria, 
and quahty control parameters; 6. educate users through commu- 
nication of standard guidelines; and 7. foster malogue with users of 
these methods and those who supply them. 
The ultimate purpose of the Subcommittee’s mission is to provide 
useful dormation to enable laboratories to assist the cliniaan inpa- 
tient care, without making recommendations concerning the cknical 
use of spec& antimicrobial agents. 
The success of the NCCLS consensus process lies, in no small 
measure, in the assurance that all interested parties will have a place 
and be heard at the table. In concert with the NCCLS’S consensus 
process and global growth, I welcome the opportunity to exchange 
views with my European colleagues and look forward to future op- 
portunities for harmonization. 
I S122 I Vieuwpoint of the European Industry on 
susceptibility testing 
A. Bryskier. Clinical Pharmacology Anti-infem’uer HMR, Romainville, 
France 
The development of antibacterial agents is divided into numerous 
parts: One is the microbiology section which is itself split into two 
sections: the first is the antibacterial spectrum and activity includ- 
ing break points and quality control strains, and the second is the 
microbiology within the cljn~cal development (phases I1 and 111). 
One of the main concerns for the development of antibiotics is to 
obtain break-points which are the basehe of the clinical develop- 
ment and the chical introduction of the new antibacterial in clinical 
practice. The problem in Europe is very complex, some agencies 
promote their own break-points: France (CFA), United-Kingdom 
(BSAC), Sweden and Germany (DIN), other countries use NC- 
CLS recommendations as well as recommendations h m  one of the 
above-mentioned countries. 
During the Phase II/III trials, NCCLS recommendations (qual- 
ity control s t r a i n s ,  prelutllnary break-points) are usually used 
world-wide, to obtain reliable clinical and microbiological results. 
After application, break-points are “delivered” by the different 
agencies. The most acute problems are the following Merent 
break-points, diEerent loads of the test disks and the quality control 
sttains very or are not proposed. Furthermore, due to the complexity 
of the regulations, the variations in the load dose could be substantial 
among manufacturers even within different batches. 
There is an acute need w i h n  the pharmaceutical industry in 
Europe for standanbation of the methods used to determine 
break-points for the same quality control strains and the same load 
on the disks. 
The NCCLS subcommittee in the USA is now escablishmg an 
ahance with the Japanese NCCLS and is currently working with 
the Pan America Health Organization and in Brazil. 
An alliance has first to be set up in Europe and secondly with 
other organizations to obtain a consensus which will be help to 
pharmaceutical companies as well as Biodiagnostic companies. 
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No abstract available. 
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I S124 I Future of the Standardization Process 
E Baquero. E 
No abstract available 
Infection in the organ transplant patient: A 
modem Hegelian dialectic 
(Joint Symposium with the International 
lmmunocompromised Host Society) 
1 S125 I Strategies for prevention of CMV infection and 
disease in transplant recipients 
€? Ljungman. Dept. cf Hematdon, Huddinge University Hospital, 
Karolinska Institutet, Huddinge, Sweden 
The morbidity and mortality in CMV disease in solid organ and 
bone marrow transplant recipients have been reduced during the last 
decade. Several different advances in management have contributed 
to this development. In patients who are seronegative to CMV at 
the time of transplantation it is of major importance whenever pos- 
sible to prevent the transmission of CMV through se!ection of organ 
donors and the use of screened or leukocyte depleted blood prod- 
ucts. In patients who are seropositive at the time of transplantation 
or in whom a CMV negative organ is not available preventive strate- 
gies should be designed based on the risk group of the patients. In 
low risk organ transplant patients prophyhs is usually not neces- 
s a r y  but the patients should be followed with a sensitive diagnostic 
technique such as antigenemia of PCR and therapy initiated either 
on a preemptive basis or deferred dependmg on the &cal status 
of the patient. In intermediate risk patients either prophylaxis or 
an preemptive strategy could be considered while in high risk pa- 
tients antivid prophylaxis with ganciclovir has been shown to be 
effective. In bone marrow transplant patients the use of either antivi- 
ral prophylaxis or preemptive therapy based on sensitive diagnostic 
technique are essential to prevent the development of fiequently fa- 
tal CMV disease. Several merent recent developments today allow 
risk-adapted preventive strategies for prevention of CMV disease in 
transplant patients. 
Fungal infections in the solid organ transplant 
recipient 
I? Mufioz. Hospital General Universitario “Gregorio Maraibn”, Madrid, 
Spain 
Rejection and mfection are the commonest early complications of 
solid organ transplant recipients. Although viral and bacterial infec- 
tions are more ftequent, invasive fungal infections carry the highest 
morbidity and mortality rates. 
The main fungal pathogen, the c h c a l  presentation and the prog- 
nosis vary according to the type of allografc. Common risk factors 
are breakdown of cutaneous-mucosal integrity, immunosuppression, 
concurrent infections and CMV disease. 
Disseminated candidiasis and invasive pulmonary aspergdlosis are 
the most frequent mycoses that cause Me-threatening infection in 
these patients. Candida is common after procedures requiring ab- 
dominal surgery. Aspergillus predominates in heart and heart-lung re- 
cipients. Dimorphc fungi must be considered in endemic areas and 
new emerging fungal pathogens are being increasingly recognized. 
Early detection is often difficult, and an aggressive workup has to 
be performed in most instances to obtain the diagnosis antemortem. 
Amphotericin B has been the mainstay of treatment, but its use can 
be associated with significant toxicity in patients on cyclosporine. 
New drugs are avadable nowadays, although experience is s d  scarce. 
The role of antifungal prophylaxis is controversd. All these fields 
will be reviewed. 
I S127 I Cells and Cytokines in the Pathogenesis of 
Opportunistic Infections 
J.S. Remington. Stanford University, Palo Alto, C A ,  USA 
Despite remarkable advances in organ transplantation, infections due 
to opportunistic pathogens continue to cause sigmficant morbid- 
itylmortality in these patients. Cell mediated immunity and the 
lymphocyte-monocyte-macrophage arm of the immune system may 
be markedly suppressed in organ transplant recipients, primarily due 
to reaction against the allograft and the immunosuppressive drugs 
they are receiving. This problem has served as an impetus for studies 
on the immunopathogenesis of fungal, bacterial, viral and proto- 
zoan infections against whch cells and cytokines are the primary 
mechanisms of host defense. In addition to the cytotoxic potential of 
CD4+ and CD8’ T cells, Thl- and ThZcytokine expression pat- 
terns have been correlated with outcome of these mfections. Both 
immunopathology and pathogen growth is lneuenced by the bal- 
ance between these responses and resistance or susceptibility to these 
infections has been correlated with the antimicrobial Thl  and Th2 
responses respectively. Resistance against many intracellular organ- 
isms is associated with induction of a Thl  response and particu- 
larly with the macrophage-activating cytokines, IFN-y and TNF-a . 
A Thl response is also critical for most d infections although 
IFN-a/B- activated NK cells, cytolyac T lymphocytes and neutral- 
izing antibomes are also important for host resistance against viruses. 
Induction of IL-12 secretion during the early stages of many of these 
intracellular mfections is critical for initiation of IFN-y dependent 
resistance and development of a Thl response; it can also convert a 
Th2 response to a Thl  pattern. Many organisms are able to directly 
stimulate macrophages to produce IL-12 and TNF-a and thereby, 
along with IL-15, activate NK cells to produce IFN-y; this  occurs 
prior to the conventional T cell response and thereby provides one of 
the earliest (inate) responses against infectious agents. IL-12 admin- 
istered early in murine models of infection has provided protection 
against a variety of intracellular pathogens and has proved a valu- 
able adjuvant for vaccines. The role of the various cytokines, their 
cross-regulation, and their potential for treating infectious diseases 
wdl be dwussed. 
I S128 I The Indirect Effects of Infection on H o s t  
R.H. Harvard. M I T  Division cfHealth .%ewes and Ethnology, 
Cambridge, MA, USA 
Cytokines and growth factors liberated in the course of infection 
can influence the occurrence of other mfecnons, modulate the re- 
currence of allograft injury, and play a role in the process of onco- 
genesis. Evidence for this has been primarily developed by stud- 
ies of cytomegalovirus (CMV) mfection, the single most important 
mfection in transplantation. Tumor necrosis factor, whether elab- 
orated in response to allograft rejection, antilymphocyte antibody 
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